EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Population‐Based Evidence for the Use of Serum Neurofilaments as Individual Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis

Simon Witzel iD, André Huss, Gabriele Nagel, Angela Rosenbohm iD, Dietrich Rothenbacher, Raphael S Peter, Hansjörg Bäzner, Axel Börtlein, Silke Dempewolf, Martin Schabet, Martin Hecht, Andreas Kohler und 16 weitere

Annals of Neurology · 2024-12 · 96 (6) · 1040-1057

DOI: 10.1002/ana.27054 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Neurology, online erschienen am 23.08.2024. Verfasst von Simon Witzel und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Ulm University, Ulm, Germany. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Biomarkers, Neurofilament Proteins. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Neurofilament light chains (NfL) and phosphorylated neurofilament heavy chains (pNfH), established as diagnostic and prognostic biomarkers in hospital‐based amyotrophic lateral sclerosis (ALS) cohorts, are now surrogate markers in clinical trials. This study extends their evaluation to a population level, with the aim of advancing their full establishment and assessing the transferability of biomarker findings from controlled cohorts to real‐world ALS populations.

Methods

We measured serum NfL and pNfH levels in all ALS patients (n = 790) and general population controls (n = 570) with available baseline samples participating in the epidemiological ALS Registry Swabia, providing platform‐specific (ELLA™) reference data and Z‐scores for controls, as well as reference data, disease‐specific Z‐scores and longitudinal data in ALS. We evaluated the diagnostic and prognostic utility of neurofilaments and quantified the impact of ALS‐related factors and non‐ALS confounders.

Results

Neurofilaments showed high diagnostic and prognostic utility at the population level, with NfL superior to pNfH. The novel concept of a population‐based ALS Z‐score significantly improved the prognostic utility compared to absolute raw values. Both biomarkers increased more strongly with age in controls than in ALS, and age adjustment improved diagnostic accuracy. Our data show that disease progression rates, ALS phenotype, body mass index (BMI), and renal function need to be considered when interpreting neurofilament levels; longitudinal neurofilament levels were generally stable in individual patients, especially when adjusted for age and baseline levels.

Interpretation

Population‐based assessment enhances the utility of particularly serum NfL as a diagnostic and prognostic biomarker in ALS and improves the translation of findings from controlled cohorts to real‐world populations. ANN NEUROL 2024;96:1040–1057

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisBiomarkersNeurofilament ProteinsHumansMiddle AgedFemaleMaleAgedPrognosisIntermediate FilamentsAdult

Substanzen

BiomarkersNeurofilament Proteinsneurofilament protein Lneurofilament protein H

Autor:innen und Institutionen

  • Department of Neurology, Ulm University, Ulm, Germany.
  • Institute for Epidemiology and Medical Biometry, Ulm University, Ulm, Germany.
  • Department of Neurology, Klinikum Stuttgart, Katharinenhospital, Stuttgart, Germany.
  • Department of Neurology, RKH Klinikum Ludwigsburg, Ludwigsburg, Germany.
  • Department of Neurology, Klinikum Kaufbeuren, Kliniken Ostallgaeu-Kaufbeuren, Kaufbeuren, Germany.
  • Department of Neurology, Klinikum am Gesundbrunnen Heilbronn, Heilbronn, Germany.

ORCID-Profile: Simon Witzel, Angela Rosenbohm, David Brenner, Johannes Dorst

Förderung

  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Witzel, S., Huss, A., Nagel, G., Rosenbohm, A., Rothenbacher, D., Peter, R. S., Bäzner, H., Börtlein, A., Dempewolf, S., Schabet, M., Hecht, M., Kohler, A., Opherk, C., Naegele, A., Sommer, N., Lindner, A., Alexudis, C., Bachhuber, F., Halbgebauer, S., …, & the ALS Registry Swabia Study Group (2024). Population‐Based Evidence for the Use of Serum Neurofilaments as Individual Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis. Annals of Neurology, 96(6), 1040-1057. https://doi.org/10.1002/ana.27054

Vancouver

Witzel S, Huss A, Nagel G, Rosenbohm A, Rothenbacher D, Peter RS, et al. Population‐Based Evidence for the Use of Serum Neurofilaments as Individual Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis. Annals of Neurology. 2024;96(6):1040-1057. doi:10.1002/ana.27054

BibTeX
@article{Witzel2024,
  author = {Witzel, Simon and Huss, André and Nagel, Gabriele and Rosenbohm, Angela and Rothenbacher, Dietrich and Peter, Raphael S and Bäzner, Hansjörg and Börtlein, Axel and Dempewolf, Silke and Schabet, Martin and Hecht, Martin and Kohler, Andreas and Opherk, Christian and Naegele, Andrea and Sommer, Norbert and Lindner, Alfred and Alexudis, Christoforos and Bachhuber, Franziska and Halbgebauer, Steffen and Brenner, David and Ruf, Wolfgang and Weiland, Ulrike and Mayer, Benjamin and Schuster, Joachim and Dorst, Johannes and Tumani, Hayrettin and Ludolph, Albert C and the ALS Registry Swabia Study Group, the ALS Registry Swabia Study Group},
  title = {Population‐Based Evidence for the Use of Serum Neurofilaments as Individual Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis},
  journal = {Annals of Neurology},
  year = {2024},
  volume = {96},
  number = {6},
  pages = {1040--1057},
  doi = {10.1002/ana.27054}
}
Kostenlos starten →